BACKGROUND AND AIMS: Elderly nursing home residents are especially prone to a severe course of SARS-CoV-2 infection. In this study, we aimed to investigate the complex immune response after vaccination depending on the convalescence status and vaccine. METHODS: Sampling took place in September-October 2021. IgG antibodies against spike protein and nucleocapsid protein, the titer of virus neutralization antibodies against delta and (on a subset of patients) omicron, and cellular immunity (interferon-gamma release assay) were tested in nursing home residents vaccinated with Pfizer, Moderna (both 30-31 weeks after the completion of vaccination), or AstraZeneca (23 weeks) vaccines. The prevalence with 95% confidence intervals (CI) was evaluated in Stata version 17. RESULTS: 95.2% (95% CI: 92.5-97.1%) of the 375 participants had positive results of anti-S IgG, 92.8% (95% CI: 89.7-95.2%) were positive in virus neutralization assay against delta, and 89.0% (95% CI: 84.5-92.5%) in the interferon-gamma-releasing assay detecting cellular immunity. Results of the virus neutralization assay against omicron correlated with those against delta but the neutralization capacity was reduced by about half. As expected, the worst results were found for the AstraZeneca vaccine, although the vaccination-to-test period was the shortest for this vaccine. All immune parameters were significantly higher in convalescent residents than in naive residents after vaccination. No case of COVID-19 occurred during the vaccination-to-test period. CONCLUSIONS: A high immune response, especially among vaccinated convalescents (i.e., residents with hybrid immunity), was found in elderly nursing home residents 5-7 months after vaccination against SARS-CoV-2. In view of this, it appears that such residents are much better protected from COVID-19 than those who are only vaccinated and the matter of individual approach to the booster dose in such individuals should be further discussed.

Centre for Health Research Faculty of Medicine University of Ostrava Syllabova 19 703 00 Ostrava Czech Republic

Department of Epidemiology and Public Health Faculty of Medicine University of Ostrava Syllabova 19 703 00 Ostrava Czech Republic

Institute of Public Health Ostrava Partyzánské náměstí 7 702 00 Ostrava Czech Republic

Institute of Public Health Ústí nad Labem Moskevská 1531 15 400 01 Ústí nad Labem Czech Republic

Zobrazit více v PubMed

Goldberg Y., Mandel M., Bar-On Y.M., Bodenheimer O., Freedman L., Ash N., Alroy-Preis S., Huppert A., Milo R. Protection and waning of natural and hybrid COVID-19 immunity. Medrxiv Prepr. Serv. Health Sci. 2021 doi: 10.1101/2021.12.04.21267114. PubMed DOI PMC

Havervall S., Ng H., Jernbom Falk A., Greilert-Norin N., Månberg A., Marking U., Laurén I., Gabrielsson L., Salomonsson A.-C., Aguilera K., et al. Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19. J. Intern. Med. 2022;291:72–80. doi: 10.1111/joim.13387. PubMed DOI PMC

León T.M., Dorabawila V., Nelson L., Lutterloh E., Bauer U.E., Backenson B., Bassett M.T., Henry H., Bregman B., Midgley C.M., et al. COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis—California and New York, May–November 2021. Morb. Mortal. Wkly. Rep. 2022;71:125–131. doi: 10.15585/mmwr.mm7104e1. PubMed DOI PMC

Blain H., Tuaillon E., Gamon L., Pisoni A., Miot S., Rolland Y., Picot M.-C., Bousquet J. Antibody response after one and two jabs of the BNT162b2 vaccine in nursing home residents: The CONsort-19 study. Allergy. 2022;77:271–281. doi: 10.1111/all.15007. PubMed DOI PMC

Hartley G.E., Edwards E.S.J., Aui P.M., Varese N., Stojanovic S., McMahon J., Peleg A.Y., Boo I., Drummer H.E., Hogarth P.M., et al. Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. Sci. Immunol. 2020;5:eabf8891. doi: 10.1126/sciimmunol.abf8891. PubMed DOI PMC

Figueiredo-Campos P., Blankenhaus B., Mota C., Gomes A., Serrano M., Ariotti S., Costa C., Nunes-Cabaço H., Mendes A.M., Gaspar P., et al. Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset. Eur. J. Immunol. 2020;50:2025–2040. doi: 10.1002/eji.202048970. PubMed DOI PMC

Post N., Eddy D., Huntley C., van Schalkwyk M.C.I., Shrotri M., Leeman D., Rigby S., Williams S.V., Bermingham W.H., Kellam P., et al. Antibody response to SARS-CoV-2 infection in humans: A systematic review. PLoS ONE. 2020;15:e0244126. doi: 10.1371/journal.pone.0244126. PubMed DOI PMC

Geisen U.M., Sümbül M., Tran F., Berner D.K., Reid H.M., Vullriede L., Ciripoi M., Longardt A.C., Hoff P., Morrison P.J., et al. Humoral protection to SARS-CoV2 declines faster in patients on TNF alpha blocking therapies. RMD Open. 2021;7:e002008. doi: 10.1136/rmdopen-2021-002008. PubMed DOI PMC

Irsara C., Egger A.E., Prokop W., Nairz M., Loacker L., Sahanic S., Pizzini A., Sonnweber T., Holzer B., Mayer W., et al. Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers. Clin. Chem. Lab. Med. (CCLM) 2021;59:1453–1462. doi: 10.1515/cclm-2021-0214. PubMed DOI

Mendrone-Junior A., Dinardo C.L., Ferreira S.C., Nishya A., Salles N.A., de Almeida Neto C., Hamasaki D.T., Facincani T., de Oliveira Alves L.B., Machado R.R.G., et al. Correlation between SARS-CoV-2 antibody screening by immunoassay and neutralizing antibody testing. Transfusion. 2021;61:1181–1190. doi: 10.1111/trf.16268. PubMed DOI PMC

Toor S.M., Saleh R., Sasidharan Nair V., Taha R.Z., Elkord E. T-cell responses and therapies against SARS-CoV-2 infection. Immunology. 2021;162:30–43. doi: 10.1111/imm.13262. PubMed DOI PMC

Murugesan K., Jagannathan P., Pham T.D., Pandey S., Bonilla H.F., Jacobson K., Parsonnet J., Andrews J.R., Weiskopf D., Sette A., et al. Interferon-γ Release Assay for Accurate Detection of Severe Acute Respiratory Syndrome Coronavirus 2 T-Cell Response. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2021;73:e3130–e3132. doi: 10.1093/cid/ciaa1537. PubMed DOI PMC

Mehta H.B., Li S., Goodwin J.S. Risk Factors Associated with SARS-CoV-2 Infections, Hospitalization, and Mortality among US Nursing Home Residents. JAMA Netw Open. 2021;4:e216315. doi: 10.1001/jamanetworkopen.2021.6315. PubMed DOI PMC

Collier D.A., Ferreira I.A.T.M., Kotagiri P., Datir R.P., Lim E.Y., Touizer E., Meng B., Abdullahi A., Baker S., Dougan G., et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature. 2021;596:417–422. doi: 10.1038/s41586-021-03739-1. PubMed DOI PMC

Witkowski W., Gerlo S., De Smet E., Wejda M., Acar D., Callens S., Heytens S., Padalko E., Vercruysse H., Cools P., et al. Humoral and Cellular Responses to COVID-19 Vaccination Indicate the Need for Post-Vaccination Testing in Frail Population. Vaccines. 2022;10:260. doi: 10.3390/vaccines10020260. PubMed DOI PMC

Mravčík V., Husa P., Kumpanová Valachovičová S., Vobořil J. Pokles hladiny neutralizačních protilátek po očkování proti SARS-CoV-2 u seniorů: Výsledky observační studie v Jihomoravském kraji. Epidemiol. Mikrobiol. Imunol. :2022. in press. PubMed

Šimánek V., Pecen L., Krátká Z., Fürst T., Řezáčková H., Topolčan O., Fajfrlík K., Sedláček D., Šín R., Pazdiora P., et al. Five Commercial Immunoassays for SARS-CoV-2 Antibody Determination and Their Comparison and Correlation with the Virus Neutralization Test. Diagnostics. 2021;11:593. doi: 10.3390/diagnostics11040593. PubMed DOI PMC

Cohn B.A., Cirillo P.M., Murphy C.C., Krigbaum N.Y., Wallace A.W. SARS-CoV-2 vaccine protection and deaths among US veterans during 2021. Science. 2021;375:331–336. doi: 10.1126/science.abm0620. PubMed DOI PMC

Eyre D.W., Taylor D., Purver M., Chapman D., Fowler T., Pouwels K.B., Walker A.S., Peto T.E. The impact of SARS-CoV-2 vaccination on Alpha & Delta variant transmission. Medrxiv Prepr. Serv. Health Sci. 2021 doi: 10.1101/2021.09.28.21264260. DOI

Mazagatos C., Monge S., Olmedo C., Vega L., Gallego P., Martín-Merino E., Sierra M.J., Limia A., Larrauri A. Effectiveness of mRNA COVID-19 vaccines in preventing SARS-CoV-2 infections and COVID-19 hospitalisations and deaths in elderly long-term care facility residents, Spain, weeks 53 2020 to 13 2021. Eurosurveillance. 2021;26:2100452. doi: 10.2807/1560-7917.ES.2021.26.24.2100452. PubMed DOI PMC

Berec L., Šmíd M., Přibylová L., Májek O., Pavlík T., Jarkovský J., Zajíček M., Weiner J., Barusová T., Trnka J. Real-life protection provided by vaccination, booster doses and previous infection against COVID-19 infection, hospitalisation or death over time in the Czech Republic: A whole country retrospective view. Medrxiv Prepr. Serv. Health Sci. 2021 doi: 10.1101/2021.12.10.21267590. DOI

Pierobon A., Zotto A.D., Antico A., De Antoni M.E., Vianello L., Gennari M., Di Caprio A., Russo F., Brambilla G., Saugo M. Outbreak of SARS-CoV-2 B.1.617.2 (delta) variant in a nursing home 28 weeks after two doses of mRNA anti-COVID-19 vaccines: Evidence of a waning immunity. Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis. 2021;28:614.e5–614.e7. doi: 10.1016/j.cmi.2021.12.013. PubMed DOI PMC

San Segundo D., Comins-Boo A., Lamadrid-Perojo P., Irure-Ventura J., Castillo-Otí J.M., Wallman R., Calvo-Montes J., Méndez-Legaza J.M., Baamonde-Calzada C., Sánchez-Molina I., et al. COVID-19 mRNA Based Vaccine Immune-Response Assessment in Nursing Home Residents for Public Health Decision. Vaccines. 2021;9:1429. doi: 10.3390/vaccines9121429. PubMed DOI PMC

Homza M., Zelena H., Janosek J., Tomaskova H., Jezo E., Kloudova A., Mrazek J., Svagera Z., Prymula R. COVID-19 antigen testing: Better than we know? A test accuracy study. Infect. Dis. 2021;53:661–668. doi: 10.1080/23744235.2021.1914857. PubMed DOI PMC

Pannus P., Neven K.Y., De Craeye S., Heyndrickx L., Vande Kerckhove S., Georges D., Michiels J., Francotte A., Van Den Bulcke M., Zrein M., et al. Poor antibody response to BioNTech/Pfizer COVID-19 vaccination in SARS-CoV-2 naïve residents of nursing homes. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2021:ciab998. doi: 10.1093/cid/ciab998. PubMed DOI PMC

Kontopoulou K., Nakas C.T., Ainatzoglou A., Ifantidou A., Ntotsi P., Katsioulis C., Papazisis G. Immunogenicity of the BNT162b2 Mrna COVID-19 vaccine in elderly people over 85 years of age in Greece: The GREVAXIMO study. Aging Clin. Exp. Res. 2021;33:3385–3389. doi: 10.1007/s40520-021-01997-7. PubMed DOI PMC

Khoury D.S., Cromer D., Reynaldi A., Schlub T.E., Wheatley A.K., Juno J.A., Subbarao K., Kent S.J., Triccas J.A., Davenport M.P. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 2021;27:1205–1211. doi: 10.1038/s41591-021-01377-8. PubMed DOI

Rahman M.M., Masum M.H.U., Wajed S., Talukder A. A comprehensive review on COVID-19 vaccines: Development, effectiveness, adverse effects, distribution and challenges. Virusdisease. 2022;33:1–22. doi: 10.1007/s13337-022-00755-1. PubMed DOI PMC

Gazit S., Shlezinger R., Perez G., Lotan R., Peretz A., Ben-Tov A., Cohen D., Muhsen K., Chodick G., Patalon T. Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: Reinfections versus breakthrough infections. Medrxiv Prepr. Serv. Health Sci. 2021 doi: 10.1101/2021.08.24.21262415. PubMed DOI

Shrestha N.K., Burke P.C., Nowacki A.S., Terpeluk P., Gordon S.M. Necessity of COVID-19 Vaccination in Persons Who Have Already Had COVID-19. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2022:ciac022. doi: 10.1093/cid/ciac022. PubMed DOI PMC

Kojima N., Roshani A., Brobeck M., Baca A., Klausner J.D. Incidence of SARS-CoV-2 infection among previously infected or vaccinated employees. Int. J. Infect. Dis. 2022;118:21–23. doi: 10.1016/j.ijid.2022.02.015. PubMed DOI PMC

One Year Duration of Immune Response Following a 3rd Booster Dose of mRNA Vaccine Against COVID-19 in 292 Patients With Hematological Malignancies in University Hospital Ostrava, Czech Republic